Arcturus Therapeutics (NASDAQ:ARCT) had its price objective upped by HC Wainwright from $16.00 to $18.00 in a research note released on Wednesday, BenzingaRatingsTable reports. The firm currently has a buy rating on the biotechnology company’s stock.
Several other research analysts also recently weighed in on ARCT. Brookline Capital Management restated a buy rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. Zacks Investment Research upgraded Arcturus Therapeutics from a hold rating to a buy rating and set a $10.00 price target for the company in a research note on Tuesday, July 16th. ValuEngine downgraded Arcturus Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 1st. Finally, Chardan Capital set a $18.00 target price on Arcturus Therapeutics and gave the company a buy rating in a research report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. Arcturus Therapeutics currently has an average rating of Buy and a consensus target price of $15.33.
ARCT stock traded up $0.37 during midday trading on Wednesday, hitting $10.46. The company’s stock had a trading volume of 83,184 shares, compared to its average volume of 120,747. Arcturus Therapeutics has a 12 month low of $4.11 and a 12 month high of $15.50. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. The company has a market capitalization of $132.40 million, a price-to-earnings ratio of -4.84 and a beta of 2.36. The business has a 50 day moving average price of $10.28.
Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at approximately $128,000. Creative Planning bought a new position in shares of Arcturus Therapeutics during the 1st quarter valued at approximately $416,000. Nikko Asset Management Americas Inc. bought a new position in shares of Arcturus Therapeutics during the 1st quarter valued at approximately $438,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at approximately $1,227,000. Finally, ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 13.7% during the 1st quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after acquiring an additional 111,968 shares during the last quarter. Hedge funds and other institutional investors own 12.66% of the company’s stock.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Featured Article: Depreciation
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.